Non-Hodgkin\'s lymphoma (NHL) is a clinically and molecularly heterogeneous group of malignant lymphoproliferative diseases. Diffuse large B cell NHL (DLBCL) is the most common subtype followed by indolent or low-grade lymphomas \[follicular lymphoma (FL), being the most common subtype among indolent-type lymphoma\]. Addition of anti-CD20 therapy (immunotherapy, rituximab) to cyclophosphamide, doxorubicin, vincristine and prednisone results in cure in over half of the patients and is currently the standard of care. For asymptomatic, low-tumour burden FL, a \'wait-and-watch\' policy is generally followed. Early-stage FL is treated with local radiation. For symptomatic FL the first-line treatment is chemo-immunotherapy followed by two-year maintenance therapy with anti-CD20 monoclonal antibodies. The CD20 antigen is a transmembrane protein that acts as a calcium channel and plays a key role in cell cycle progression and differentiation of B cells. CD20 antigen is present in approximately 9 per cent of peripheral blood mononuclear fraction and \>90 per cent of B cells from blood and lymphoid organs. Lymphoma cells from \>90 per cent of patients with B cell NHL express this antigen. Therefore, CD20 is an attractive target molecule in the treatment of B cell NHL.

A number of radionuclides are being used in medicine either for diagnosis or therapy. Monoclonal antibodies are considered efficient carriers for radionuclides to be delivered to the target (also called radio-immunotherapy, RIT). Radiolabelled compounds (therapeutic radiopharmaceuticals) once administered reach to the target molecule present on the surface of tumour cells and directly interact with these cells. The ^90^yttrium (^90^Y)-labelled ibritumomab tiuxetan is one such therapeutic radiopharmaceutical that conjugates an anti-CD20 monoclonal antibody with the beta-emitting radionuclide ^90^Y using the chelating agent tiuxetan; ^90^Y is a pure beta emitter with a half-life of 64 h (2.7 days) that decays to ^90^Zr. It has an effective path length of 5.3 mm, meaning that 90 per cent of its energy is absorbed within a sphere with 5.3 mm radius.

Ibritumomab tiuxetan, the ^90^Y immunotherapy (^90^Y-IT), was approved for the treatment of relapsed indolent or low-grade FLs or transformed B cell NHL and for patients with rituximab-refractory follicular NHL. This therapy should be considered for patients with indolent lymphoma in the first relapse, who have tumour long-axis diameter ≤2.5 cm and SUV~max~≤6.5. ^90^Y-IT improves the response rate and outcomes of relapsed/refractory DLBCL patients and in mantle cell lymphoma (MCL) where it has been used to treat minimal residual disease (as consolidation) after first-line chemotherapy. In addition to RIT, recently, there has been development of new classes of highly effective immunotherapeutic approaches including chimeric antigen receptor T cell therapy that are designed to bypass cancer immune evasion.

This book is arranged in 10 chapters: the first chapter gives a comprehensive overview of the clinical use, efficacy, toxicity and safety profile of ibritumomab. ^90^Y-IT uses an antibody to mediate complement-mediated cytotoxicity, along with the delivery of high-energy, short path length (5 mm) beta irradiation from ^90^Y to both CD20-lymphoma cells and neighbouring tumour cells that are inaccessible to the antibody or have insufficient antigen expression as a result of a cross-fire effect, with little effect on other solid organs. The expected short-term toxicity associated with ^90^Y-IT is mainly reversible myelosuppression followed by the potential development of myelodysplastic syndrome and secondary leukaemia in long term. The second chapter deals with the biology and pathology of B cell lymphomas. The heterogeneity of B cell NHL is nicely captured through WHO classification and the cellular origin of B of mature B cell neoplasms. Better understanding of the microenvironmental interactions in B cell lymphomas has led to the identification of targets and development of newer targeted therapies. The third chapter deals with the issue of resistance to ^90^Y ibritumomab tiuxetan therapy. It has been suggested that bulky disease, downregulation of CD20 or activation of NF-kB or a combination of these factors is the potential cause of resistance to ^90^Y-IT.

The next three chapters deal with the characteristics of ibritumomab, radiation dosimetry and response evaluation. ^18^F-fluorodeoxyglucose positron emission tomography (^18^F-FDG PET)/computed tomography scan is currently the standard investigation for the evaluation of response for lymphoma. Negative PET finding at three months after ^90^Y-IT is highly predictive of complete response. However, metabolic response to ^90^Y-IT could be gradual with continued declines of FDG uptake occurring between 7 and 9 months after therapy; therefore, PET-positive result after three months does not warrant immediate additional therapy.

The subsequent chapter deals with the preparation and schedule of ^90^Y-IT administration, resistance and heterogeneity of intratumoral antibody distribution and data on radiation dosimetry for patients receiving ibritumomab therapy. The authors described combining radionuclide therapy and other immune-based therapies to overcome resistance in cancer. In the concluding chapter the authors describe prospects for enhancing the efficacy of RIT which has been little utilized because of a variety of medical, financial and logistic obstacles. Newer technologies employing multistep \'pre-targeting\' methods, particularly those utilizing bi-specific antibodies, have greatly enhanced the therapeutic efficacy of RIT and diminished its toxicities.

This multi-authored book serves as a reference book on the use of RIT in the treatment of B cell indolent-type lymphoma with good summary of data, potential mechanisms of resistance and possible options for minimizing resistance and improving results. A few details are missing, especially data on DLBCL, MCL, high-dose chemotherapy and stem cell transplant would have been of interest.

Overall, the book will be a useful companion for oncologists, lymphoma pathologists, nuclear medicine specialists, researchers and physicians involved in the management of lymphomas with radionuclide therapy. This would be a good reference book in the medical libraries.
